Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- NHO to Use Fewer Psychoneurotics, Respiratory Drugs
September 10, 2007
- BUSINESS NEWS IN BRIEF
September 10, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 10, 2007
- Zeria Licenses TM-411 from TMRC
September 10, 2007
- SURVEY／Many Patients Still Want Hospital-Based Doctors to Serve as Attending Physicians
September 10, 2007
- Takeda Begins PII Trial for TAK-536 for Hypertension
September 10, 2007
- TOPICS／Pharma Delegates Launches 2007/2008 Season
September 10, 2007
- JCL Bioassay to Start "Cold" MD Studies
September 10, 2007
- Political Science Scholar with Personal
September 10, 2007
- NEW PRODUCTS／Daiichi Sankyo: Fentanyl for Infants
September 10, 2007
- RIKEN Kobe Institute to Develop
September 10, 2007
- Takeshi Erikawa Appointed
September 10, 2007
- Korosho to Train Senior CRCs, Data Managers, IRB Members
September 10, 2007
- Korosho to Demand \22,160.4 Bil., Up 3.2%, in FY2008
September 10, 2007
- Korosho to Standardize Forms for Clinical Trial Documents
September 10, 2007
- Japan's 1st Drug for ADHD Recommended for Approval
September 10, 2007
- R&D NEWS IN BRIEF
September 10, 2007
- Korosho to Create "Healthcare Clusters" to Promote Drug Discovery
September 10, 2007
- Our Generics Had Economic Effects of \58.6 Bil. in 2006: Taiyo Yakuhin
September 10, 2007
- JMA Proposes Same Prices for Original Drugs and Generics
September 10, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…